The European Healthcare Innovation Leadership Network focused on advancing European healthcare innovation to address unmet needs and ensure patient access to valuable treatments in an era of severe budgetary pressures.
From 2006 through 2012, the network brought together European healthcare leaders committed to improving patient well-being. Members included public- and private-sector leaders who represented regulators, health technology assessors (HTA), healthcare budget holders, patient representatives, civil society, and medicine developers. The network was supported by AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Johnson & Johnson.
The network succeeded in piloting a new way for diverse stakeholders to engage critical questions about medicines in development, enabling health systems to provide the right medicines to the right patients at the right time.
European Member States and healthcare leaders are under significant pressure as they face the dilemma of fewer healthcare resources per capita to meet increasing demand for health services. Underlying this challenge are ageing populations, declining rates of workforce participation, budgetary pressure, and the concurrent introduction of new treatments that are both dramatically more effective and costly. In an effort to address these challenges, healthcare leaders met to discuss the need for outcomes-based approaches to maximize patient benefit and deliver value to health systems and society.
Premier healthcare leaders from across Europe agreed that the time for “admiring the problem” is over. The turbulent economic climate continues to erode healthcare budgets and jeopardize future innovation, health system performance and patient outcomes. Participants favor increased collaboration and novel approaches to healthcare delivery in order to mitigate the detrimental effects of the financial crisis felt by institutions and organizations.
Participants were hopeful about opportunities “to drive a higher level of innovation in healthcare,” whether by augmenting the voice of the patient, increasing the predictability of health system needs, aligning on valuation systems in medicine or transforming the role of companies in healthcare delivery. The multi-stakeholder consultations in drug development are examples of the value that can be realized through such collaboration.
The activities of the Network led to the launch of a new pilot process for multi-country, multi-stakeholder consultations in drug development.
In 2009, Tapestry convened Type-2 Diabetes and Breast Cancer Working Groups of medical experts, regulators, payers, reimbursement authorities, patients, and the pharmaceutical industry to develop disease-specific value frameworks.
European Healthcare Innovation Leadership Network
Former Company Group Chairman, Global Pharmaceuticals, Johnson & Johnson